Fred Hutch bioengineer Dr. Matthias Stephan is working to develop a special foam that could help make gene therapy for blood ...

Non-exclusive license providing Solid’s proprietary, next-generation capsid, AAV-SLB101, to Andelyn Biosciences, a ...

Cincinnati Children's today celebrated the opening of a new state-of-art facility for its Applied Gene and Cell Therapy Center, which will enable the health system to increase clinical trials of ...

By adding a microRNA molecule to ALS models, Tel Aviv University, Ben-Gurion University and Weizmann Institute researchers ...

AAV-SLB101 is a rationally designed capsid developed for enhanced skeletal muscle, cardiac tropism, and reduced biodistribution to the liver.

Andelyn Biosciences has entered a non-exclusive worldwide license and collaboration agreement with Solid Biosciences Inc. for ...

Sarepta has received US FDA approval for updated prescribing information for Elevidys, an AAV-based gene transfer therapy.

Quality, stability, sustainability, and the increased and thoughtful integration of artificial intelligence are foremost in the minds of those on the leading edge of testing trends.

In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the ...

A new discovery from the lab of YouYang Zhao, Ph.D., from Stanley Manne Children's Research Institute at Ann & Robert H.

This biotech has already made impressive contributions to medicine, and it could make more. But does that make it a buy?